Zeng FenFei, Pan QiHong, Wang XuTao, Wang Zhen, Ni JiaYan
From the Department of cardiology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing City, Zhejiang province, China.
Department of pharmacy, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing City, Zhejiang province, China.
Cardiol Rev. 2024 Dec 11. doi: 10.1097/CRD.0000000000000830.
This study is to assess the efficacy and safety of endovascular treatment for acute ischemic stroke resulting from intracranial atherosclerosis-large vessel occlusion (ICAS-LVO) in comparison to embolic-large vessel occlusion (embolic-LVO). We undertook an extensive search of databases including PubMed, Embase, The Cochrane Library, Wanfang Data, and China National Knowledge Internet using a combination of free-text terms and mesh terms as part of our search strategy. Literature screening and data retrieval were conducted following predefined inclusion/exclusion criteria. The search timeframe was limited to studies published until August 2021. All statistical evaluations were carried out by Review Manager 5.3. This meta-analysis comprised a total of 2748 patients across 14 studies. Our results demonstrate a significantly lower rate of systematic intracranial hemorrhage in ICAS-LVO compared with embolic-LVO following endovascular therapy. Moreover, the rates of rescue therapy and stent implantation were significantly lower in ICAS-LVO versus embolic-LVO. However, the 2 groups had a similar recanalization rate, favorable outcome, and mortality rates at 90 days post endovascular treatment. Patients with ICAS-LVO exhibit a lower incidence of systematic intracranial hemorrhage after treatment compared with those with embolic-LVO. Furthermore, ICAS-LVO patients did not demonstrate a unique risk profile regarding recanalization, favorable outcomes (at 90 days), and mortality (at 90 days), resulting in comparable outcomes to embolic-LVO. However, a higher proportion of stent implantation and rescue therapy was observed in ICAS-LVO patients, highlighting the need for further investigation into the standardization of endovascular management for ICAS-LVO.
本研究旨在评估血管内治疗颅内动脉粥样硬化性大血管闭塞(ICAS-LVO)所致急性缺血性卒中与栓塞性大血管闭塞(embolic-LVO)相比的疗效和安全性。作为搜索策略的一部分,我们使用自由文本词和医学主题词相结合的方式,对包括PubMed、Embase、Cochrane图书馆、万方数据和中国知网在内的数据库进行了广泛搜索。按照预先定义的纳入/排除标准进行文献筛选和数据检索。搜索时间范围限于截至2021年8月发表的研究。所有统计评估均由Review Manager 5.3进行。这项荟萃分析共纳入了14项研究中的2748例患者。我们的结果表明,血管内治疗后,ICAS-LVO患者系统性颅内出血的发生率显著低于embolic-LVO患者。此外,ICAS-LVO患者的补救治疗率和支架植入率显著低于embolic-LVO患者。然而,两组在血管内治疗后90天的再通率、良好结局率和死亡率相似。与embolic-LVO患者相比,ICAS-LVO患者治疗后系统性颅内出血的发生率较低。此外,ICAS-LVO患者在再通、良好结局(90天时)和死亡率(90天时)方面没有表现出独特的风险特征,其结局与embolic-LVO相当。然而,ICAS-LVO患者中观察到较高比例的支架植入和补救治疗,这突出表明需要进一步研究ICAS-LVO血管内治疗的标准化。